AtriCure Q1 revenue $141.2M (+14.3%); corrects FY2026 guidance to rev $600-610M, adj EBITDA $80-82M

AtriCure, Inc.

2026-Q1 EPS reported $0.00 revenue$141,249,000

Q1 revenue $141.2M (+14.3% YoY); net income $0.1M, breakeven EPS.
U.S. rev growth 14.9% driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp.
Adjusted EBITDA $17.1M, up 95% YoY; gross margin 77.4% (+246 bps).
Corrected FY2026 guidance: revenue $600-610M, adj EBITDA $80-82M, adj EPS $0.09-0.15, net EPS $0.00-0.04.
International revenue $25.0M (+11.5% as reported; +3.3% constant currency).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AtriCure, Inc. reported the first quarter ended March 31, 2026 results: revenue $141.2 million, net income $0.1 million, EPS $0.00.

Period: the first quarter ended March 31, 2026
Revenue: $141.2 million
Net income: $0.1 million
EPS: $0.00
Result: reported results

Exact text from the filing

First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year • First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million

View on SEC.gov

Browse all earnings releases →

AtriCure, Inc. filing history →

Source: SEC EDGAR

accession 0001323885-26-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.